Published in Circulation on February 09, 1999
A noninvasive imaging modality for cardiac arrhythmias. Circulation (2000) 2.40
Computational biology in the study of cardiac ion channels and cell electrophysiology. Q Rev Biophys (2006) 1.60
LQT4 gene: the "missing" ankyrin. Mol Interv (2003) 1.01
Relation between QT duration and maximal wall thickness in familial hypertrophic cardiomyopathy. Heart (2002) 0.92
The long QT syndrome. Indian Pacing Electrophysiol J (2002) 0.82
Mean and variability of QT-interval: Relevance to psychiatric illness and psychotropic medication. Indian J Psychiatry (2009) 0.81
Clinical applicability of molecular biology: the case of the long QT syndrome. Curr Control Trials Cardiovasc Med (2000) 0.78
LQT1 mutations in KCNQ1 C-terminus assembly domain suppress IKs using different mechanisms. Cardiovasc Res (2014) 0.77
HRS policy statement: clinical cardiac electrophysiology fellowship curriculum: update 2011. Heart Rhythm (2011) 0.75
The mitochondrial DNA mutations associated with cardiac arrhythmia investigated in an LQTS family. Iran J Basic Med Sci (2014) 0.75
Cardiogenetic counselling in a non-university hospital. Neth Heart J (2007) 0.75
Sudden intrauterine unexplained death: time for change. J Prenat Med (2012) 0.75
Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med (2009) 12.63
SCN5A mutations associated with an inherited cardiac arrhythmia, long QT syndrome. Cell (1995) 7.73
Spectrum of mutations in long-QT syndrome genes. KVLQT1, HERG, SCN5A, KCNE1, and KCNE2. Circulation (2000) 7.50
Genotype-phenotype correlation in the long-QT syndrome: gene-specific triggers for life-threatening arrhythmias. Circulation (2001) 7.47
Positional cloning of a novel potassium channel gene: KVLQT1 mutations cause cardiac arrhythmias. Nat Genet (1996) 7.35
Genetic basis and molecular mechanism for idiopathic ventricular fibrillation. Nature (1998) 7.26
A dynamic model of the cardiac ventricular action potential. I. Simulations of ionic currents and concentration changes. Circ Res (1994) 6.93
Effectiveness and limitations of beta-blocker therapy in congenital long-QT syndrome. Circulation (2000) 5.09
Mutations in the gene encoding lamin A/C cause autosomal dominant Emery-Dreifuss muscular dystrophy. Nat Genet (1999) 5.04
A model of the ventricular cardiac action potential. Depolarization, repolarization, and their interaction. Circ Res (1991) 4.91
Ionic mechanisms of propagation in cardiac tissue. Roles of the sodium and L-type calcium currents during reduced excitability and decreased gap junction coupling. Circ Res (1997) 4.86
Ionic mechanisms responsible for the electrocardiographic phenotype of the Brugada syndrome are temperature dependent. Circ Res (1999) 4.57
Identification of a deletion in plakoglobin in arrhythmogenic right ventricular cardiomyopathy with palmoplantar keratoderma and woolly hair (Naxos disease). Lancet (2000) 4.54
Long QT syndrome patients with mutations of the SCN5A and HERG genes have differential responses to Na+ channel blockade and to increases in heart rate. Implications for gene-specific therapy. Circulation (1995) 4.48
Differentiation of heart failure related to dilated cardiomyopathy and coronary artery disease using gadolinium-enhanced cardiovascular magnetic resonance. Circulation (2003) 4.48
Mutations in the genes for cardiac troponin T and alpha-tropomyosin in hypertrophic cardiomyopathy. N Engl J Med (1995) 4.37
The management of hypertrophic cardiomyopathy. N Engl J Med (1997) 4.15
Operational implementation of prospective genotyping for personalized medicine: the design of the Vanderbilt PREDICT project. Clin Pharmacol Ther (2012) 4.05
Sodium channel blockers identify risk for sudden death in patients with ST-segment elevation and right bundle branch block but structurally normal hearts. Circulation (2000) 3.99
The long QT syndrome. Prospective longitudinal study of 328 families. Circulation (1991) 3.99
A novel mutation in the potassium channel gene KVLQT1 causes the Jervell and Lange-Nielsen cardioauditory syndrome. Nat Genet (1997) 3.79
ECG T-wave patterns in genetically distinct forms of the hereditary long QT syndrome. Circulation (1995) 3.79
The long Q-T syndrome. Am Heart J (1975) 3.75
The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest (1998) 3.66
Spectrum of clinicopathologic manifestations of arrhythmogenic right ventricular cardiomyopathy/dysplasia: a multicenter study. J Am Coll Cardiol (1997) 3.64
Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy. Clin Pharmacol Ther (2011) 3.53
Detecting drug interactions from adverse-event reports: interaction between paroxetine and pravastatin increases blood glucose levels. Clin Pharmacol Ther (2011) 3.50
Linking a genetic defect to its cellular phenotype in a cardiac arrhythmia. Nature (1999) 3.41
Influence of genotype on the clinical course of the long-QT syndrome. International Long-QT Syndrome Registry Research Group. N Engl J Med (1998) 3.41
Exaggerated anesthetic requirements in the preferentially anesthetized brain. Anesthesiology (1993) 3.37
QT interval prolongation as predictor of sudden death in patients with myocardial infarction. Circulation (1978) 3.32
Action potential and contractility changes in [Na(+)](i) overloaded cardiac myocytes: a simulation study. Biophys J (2000) 3.26
Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy. Circulation (2002) 3.22
Optimizing drug outcomes through pharmacogenetics: a case for preemptive genotyping. Clin Pharmacol Ther (2012) 3.16
Low penetrance in the long-QT syndrome: clinical impact. Circulation (1999) 3.14
Taking the "idio" out of "idiosyncratic": predicting torsades de pointes. Pacing Clin Electrophysiol (1998) 3.13
TWIK-1, a ubiquitous human weakly inward rectifying K+ channel with a novel structure. EMBO J (1996) 3.06
Mutations in the laminin alpha 2-chain gene (LAMA2) cause merosin-deficient congenital muscular dystrophy. Nat Genet (1995) 3.05
Side effects of long-term amiodarone therapy. Circulation (1983) 3.03
Relation between severity of left-ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy. Lancet (2001) 3.02
Diagnosis and long-term follow-up of the Brugada syndrome in patients with idiopathic ventricular fibrillation. Eur Heart J (2001) 3.02
Proposed diagnostic criteria for the Brugada syndrome. Eur Heart J (2002) 3.01
Mutations in the cardiac myosin binding protein-C gene on chromosome 11 cause familial hypertrophic cardiomyopathy. Nat Genet (1995) 2.97
Spectrum of ST-T-wave patterns and repolarization parameters in congenital long-QT syndrome: ECG findings identify genotypes. Circulation (2000) 2.95
Task Force on Sudden Cardiac Death of the European Society of Cardiology. Eur Heart J (2001) 2.93
The emerging role of electronic medical records in pharmacogenomics. Clin Pharmacol Ther (2011) 2.93
Noninvasive electrocardiographic imaging: reconstruction of epicardial potentials, electrograms, and isochrones and localization of single and multiple electrocardiac events. Circulation (1997) 2.92
The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy. Clin Pharmacol Ther (2012) 2.90
Postmortem molecular analysis of SCN5A defects in sudden infant death syndrome. JAMA (2001) 2.89
Myosin isoenzyme redistribution in chronic heart overload. Nature (1979) 2.89
Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. J Am Coll Cardiol (2000) 2.89
Three myosin heavy-chain isozymes appear sequentially in rat muscle development. Nature (1981) 2.88
Reentry as a cause of ventricular tachycardia in patients with chronic ischemic heart disease: electrophysiologic and anatomic correlation. Circulation (1988) 2.86
Noninvasive electrocardiogram imaging of substrate and intramural ventricular tachycardia in infarcted hearts. J Am Coll Cardiol (2001) 2.85
Clinical and genetic heterogeneity of right bundle branch block and ST-segment elevation syndrome: A prospective evaluation of 52 families. Circulation (2000) 2.81
Exercise training confers anticipatory protection from sudden death during acute myocardial ischemia. Circulation (1994) 2.79
The Tangier disease gene product ABC1 controls the cellular apolipoprotein-mediated lipid removal pathway. J Clin Invest (1999) 2.77
Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin Pharmacol Ther (2013) 2.73
Myoblast transplantation for heart failure. Lancet (2001) 2.71
Multiple mechanisms in the long-QT syndrome. Current knowledge, gaps, and future directions. The SADS Foundation Task Force on LQTS. Circulation (1996) 2.70
Novel organ-specific circulating cardiac autoantibodies in dilated cardiomyopathy. J Am Coll Cardiol (1990) 2.67
Electrophysiological features of the mouse sinoatrial node in relation to connexin distribution. Cardiovasc Res (2001) 2.64
Effects of IKr and IKs heterogeneity on action potential duration and its rate dependence: a simulation study. Circulation (1999) 2.61
Quantitative changes in T helper or T suppressor/cytotoxic lymphocyte subsets that distinguish acquired immune deficiency syndrome from other immune subset disorders. Am J Med (1984) 2.60
Idiopathic long QT syndrome: progress and questions. Am Heart J (1985) 2.59
The Brugada syndrome: clinical, electrophysiologic and genetic aspects. J Am Coll Cardiol (1999) 2.56
Age- and sex-related differences in clinical manifestations in patients with congenital long-QT syndrome: findings from the International LQTS Registry. Circulation (1998) 2.53
Identification of mutations in the gene encoding lamins A/C in autosomal dominant limb girdle muscular dystrophy with atrioventricular conduction disturbances (LGMD1B). Hum Mol Genet (2000) 2.52
Cardiac myosin binding protein-C gene splice acceptor site mutation is associated with familial hypertrophic cardiomyopathy. Nat Genet (1995) 2.52
Baroreflex sensitivity and heart rate variability in the identification of patients at risk for life-threatening arrhythmias: implications for clinical trials. Circulation (2001) 2.50
Cardiac fatigue following prolonged endurance exercise of differing distances. Med Sci Sports Exerc (2000) 2.47
Relation between sexual practices and T-cell subsets in homosexually active men. Lancet (1983) 2.46
Abrupt rate accelerations or premature beats cause life-threatening arrhythmias in mice with long-QT3 syndrome. Nat Med (2001) 2.46
Early afterdepolarizations in cardiac myocytes: mechanism and rate dependence. Biophys J (1995) 2.43
Vagal stimulation and prevention of sudden death in conscious dogs with a healed myocardial infarction. Circ Res (1991) 2.41
A noninvasive imaging modality for cardiac arrhythmias. Circulation (2000) 2.40
The Pharmacogenomics Research Network Translational Pharmacogenetics Program: overcoming challenges of real-world implementation. Clin Pharmacol Ther (2013) 2.39
Myosin heavy chain messenger RNA and protein isoform transitions during cardiac hypertrophy. Interaction between hemodynamic and thyroid hormone-induced signals. J Clin Invest (1987) 2.37
Predicting clopidogrel response using DNA samples linked to an electronic health record. Clin Pharmacol Ther (2011) 2.36
Distribution of left ventricular hypertrophy in hypertrophic cardiomyopathy: a two-dimensional echocardiographic study. J Am Coll Cardiol (1983) 2.34
Inner ear defects induced by null mutation of the isk gene. Neuron (1996) 2.34
Electrocardiographic changes in 1000 highly trained junior elite athletes. Br J Sports Med (1999) 2.32
A circadian signal of change of season in patients with seasonal affective disorder. Arch Gen Psychiatry (2001) 2.32
Pathophysiology and prevention of atrial fibrillation. Circulation (2001) 2.31
Imaging dispersion of myocardial repolarization, II: noninvasive reconstruction of epicardial measures. Circulation (2001) 2.31
Cardiac sodium channel mutations in patients with long QT syndrome, an inherited cardiac arrhythmia. Hum Mol Genet (1995) 2.30
Multiple mechanisms of Na+ channel--linked long-QT syndrome. Circ Res (1996) 2.29